Actinogen Medical Ltd has released a press release.
Recruitment to close for important Alzheimers trial-XanADu
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- R&D Tax Rebate Received Totalling $3.15 Million
- Appendix 4E & Financial Statements
- DSMB reaffirms that XanADu continue without change
- XanADu Patient Enrolment Advancing Towards Completion
- Updated Xanamem Clinical Development Program
Later from Actinogen Medical
- September 2018 Quarterly Update
- Final patient enrolled in landmark Alzheimers trial-XanADu
- December 2018 Quarterly Update
- 1st participant dosed in important new Xanamem study-XanaHES
- DSMB again reaffirms XanADu trial to continue without change
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical